To determine comparative 1-year outcomes in renally impaired patients who previously underwent cardiac angiography with Isovue®-370 or Visipaque™ 320 as part of the IOP-104 trial protocol and were evaluable for determination of post-contrast significant renal injury (defined as \>25% increase in SCr or \>25% increase in cystatin C).
Study Type
OBSERVATIONAL
Enrollment
294
iodinated contrast agent either 370 stength of iopamidol or 320 strength of visipaque
Cardiovascular Associates
Birmingham, Alabama, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.